ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

House, Senate Reform Bills Move Closer To Floor Vote

August 12, 1994

Longterm Followup Finds Taxotere Improves Survival

January 25, 2008

Senate “Pleased” About Reductions In Incidence And Mortality

October 8, 1999

Kidney Cancer Group Seeks Proposals; AACR Offers Award

November 17, 1995

$3.3 Million For Retinoid Contract Awarded

October 14, 1977

Dismissed Leukemia Drug Helps CLL, Clinical Trials Find

December 26, 2008